Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome

Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared with patients with the myeloproliferative phenotype.

[1]  P. Guglielmelli,et al.  Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis , 2022, Blood Cancer Journal.

[2]  J. Mascarenhas,et al.  Thrombocytopenia in Patients With Myelofibrosis: A Practical Management Guide. , 2022, Clinical lymphoma, myeloma & leukemia.

[3]  S. Verstovsek,et al.  Momelotinib reduces transfusion requirements in patients with myelofibrosis , 2022, Leukemia & lymphoma.

[4]  S. Verstovsek,et al.  P1037: DOES EARLY INTERVENTION IN MYELOFIBROSIS IMPACT OUTCOMES? A POOLED ANALYSIS OF THE COMFORT I AND II STUDIES , 2021, HemaSphere.

[5]  S. Verstovsek,et al.  Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval , 2021, Annals of Hematology.

[6]  S. Verstovsek,et al.  Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia , 2021, Haematologica.

[7]  F. Mannelli,et al.  Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study , 2021, Leukemia.

[8]  Kaori Ito,et al.  Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. , 2020, Blood advances.

[9]  Angela G. Fleischman,et al.  ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. , 2020, Blood advances.

[10]  R. Greil,et al.  Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis , 2020, British journal of haematology.

[11]  R. Mesa,et al.  Fedratinib in myelofibrosis. , 2020, Blood advances.

[12]  S. Verstovsek,et al.  Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure , 2020, American journal of hematology.

[13]  S. Verstovsek,et al.  The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication. , 2020, Clinical lymphoma, myeloma & leukemia.

[14]  R. Mesa,et al.  Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported. , 2020, Leukemia research.

[15]  P. Guglielmelli,et al.  Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera , 2020, British journal of haematology.

[16]  R. Foà,et al.  Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis , 2019, Cancer.

[17]  R. Latagliata,et al.  Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. , 2018, Leukemia research.

[18]  S. Verstovsek,et al.  Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial , 2018, JAMA oncology.

[19]  M. Ramírez,et al.  Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia , 2018, British journal of haematology.

[20]  H. Kantarjian,et al.  Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis , 2018, European journal of haematology.

[21]  Francisco Cervantes,et al.  Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses , 2017, Journal of Hematology & Oncology.

[22]  Z. Shun,et al.  Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. , 2017, The Lancet. Haematology.

[23]  R. Fanin,et al.  Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis , 2017, Oncotarget.

[24]  R. Fanin,et al.  Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis , 2017, Oncotarget.

[25]  J. Dipersio,et al.  Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial , 2017, Journal of Hematology & Oncology.

[26]  T Giorgino,et al.  A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis , 2017, Leukemia.

[27]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[28]  Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. , 2016, Blood.

[29]  J. Cortes,et al.  Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. , 2015, JAMA oncology.

[30]  M. Cazzola,et al.  Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.

[31]  Francisco Cervantes,et al.  Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. , 2013, Blood.

[32]  M. Griesshammer,et al.  Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[34]  Francisco Cervantes,et al.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.

[35]  F. Passamonti,et al.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Cazzola,et al.  Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. , 2010, Blood.

[37]  Ayalew Tefferi,et al.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.

[38]  H. Kantarjian,et al.  Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. , 2010, Blood.

[39]  D. Dingli,et al.  Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. , 2007, Leukemia research.

[40]  P. Campbell,et al.  The myeloproliferative disorders. , 2006, The New England journal of medicine.

[41]  R. Mesa,et al.  Prognosis in transplant‐eligible patients with agnogenic myeloid metaplasia , 2006, Cancer.